2022_Oct_PODD_Boston_ Skyscraper2


Philippe Rogueda, PhD, FRSC, CChem, CSci, CIng, EURIng, Co-founder and Chief Business Officer of Merxin, is a Fellow of the Royal Society of Chemistry and OINDP expert with an accomplished track record delivering technology and global projects across R&D and commercial industrialisation. Dr Rogueda has held a number of positions in the inhaled drug delivery space, starting as a formulation scientist in the pMDI formulation labs of AstraZeneca; as a principal scientist at Novartis designing DPI, nasal and nebulised inhaled therapies; as an Executive Director of Inhaled Products R&D at Actavis/TEVA; before setting up Merxin to make inhaler technology accessible to a wider audience. Rogueda is principal consultant at Aedestra (Hong Kong), founder of Inhalation Asia (Hong Kong), and of Anthocan (UK) a company dedicated to the formulating of inhaled cannabis therapies.

More contributions